Search

Your search keyword '"Chiron, Raphaël"' showing total 210 results

Search Constraints

Start Over You searched for: Author "Chiron, Raphaël" Remove constraint Author: "Chiron, Raphaël"
210 results on '"Chiron, Raphaël"'

Search Results

3. Impact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis: A global cohort study

5. Nonsense mutations accelerate lung disease and decrease survival of cystic fibrosis children

6. Multisystemic Effects of Elexacaftor–Tezacaftor–Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease.

7. Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rareCFTRvariants: a viewpoint

8. Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study

9. Factors Associated with Asthma Severity in Children: Data from the French COBRAPed Cohort

10. Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function

11. Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis

13. COBRAPed cohort: Sensitization patterns do not differentiate children with severe asthma from those with a milder disease

15. Childhood Langerhans cell histiocytosis with severe lung involvement: a nationwide cohort study

17. Susceptibility to cefiderocol of an accurately identified collection of 147 Achromobacter clinical strains

18. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis

20. Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients

21. Central venous thrombosis and thrombophilia in cystic fibrosis: A prospective study

24. Does Achromobacter xylosoxidans have specific characteristics that could contribute to its emergence in Cystic Fibrosis ?

25. Safety and pharmacokinetics of Roscovitine (Seliciclib) in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa, a randomized, placebo-controlled study

26. Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis

27. Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease: A NTM-NET study

28. Biofilm Formation by Staphylococcus aureus in the Specific Context of Cystic Fibrosis.

31. Using chest CT scan and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis

33. Biofilm formation in MRSA isolated in Cystic Fibrosis patients is strain-dependent and differentially influenced by antibiotics

35. Rapid Improvement after Starting Elexacaftor–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease

39. The global impact of SARS-CoV-2 in 181 people with cystic fibrosis

41. Effect of one-year lumacaftor–ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients

43. DNA Methylation at ATP11A cg11702988 Is a Biomarker of Lung Disease Severity in Cystic Fibrosis: A Longitudinal Study

44. Blood co-expression modules identify potential modifier genes of diabetes and lung function in cystic fibrosis

46. CFTR p.Arg117His associated with CBAVD and other CFTR-related disorders

48. Real-Life Safety and Effectiveness of Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis

Catalog

Books, media, physical & digital resources